Dual antiplatelets therapy prescription trends and mortality outcomes among senior citizens with acute coronary syndrome: insights from the Malaysian National Cardiovascular Disease Database.

IF 1.8 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Siti Zaleha Suki, Ahmad Syadi Mahmood Zuhdi, Abqariyah Yahya, Nur Lisa Zaharan
{"title":"Dual antiplatelets therapy prescription trends and mortality outcomes among senior citizens with acute coronary syndrome: insights from the Malaysian National Cardiovascular Disease Database.","authors":"Siti Zaleha Suki, Ahmad Syadi Mahmood Zuhdi, Abqariyah Yahya, Nur Lisa Zaharan","doi":"10.26599/1671-5411.2025.02.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To examine 5-year trends and variations in dual antiplatelet therapy (DAPT) prescription among multiethnic Malaysian patients aged 60 years and older.</p><p><strong>Methods: </strong>Using the Malaysian National Cardiovascular Disease-Acute Coronary Syndrome (NCVD-ACS) registry, DAPT 5-year temporal trends prescribing patterns at discharge were examined. Multivariate logistic regression was used to calculate the adjusted odds ratio (aOR) of DAPT prescription. The 1-year all-cause mortality by Cox proportional hazard regression model (adjusted hazard ratio, aHR) using inverse proportional weighting covariates adjustment was performed to assess DAPT prognostic impacts.</p><p><strong>Results: </strong>Data of patients aged 60 years and older were extracted from 2013 to 2017 (<i>n</i> = 3718, mean age: 68 ± 6.74 years, men: 72%, and Malay ethnicity: 43%). The majority of patients were diagnosed with non-ST-segment elevation acute coronary syndrome (63%), predisposed hypertension (76%) and were overweight (74%), while only 35% of patients underwent percutaneous coronary intervention. Over the five years, there was a significant increasing trend in DAPT prescriptions (<i>P</i> < 0.001), with the aspirin-clopidogrel combination being the most common. Aspirin-ticagrelor prescriptions have also increased over the years. Variations in DAPT prescriptions were observed based on patient characteristics. Patients who underwent percutaneous coronary intervention were more likely to be prescribed DAPT in general (aOR = 2.53, 95% CI: 1.95-3.28, <i>P</i> < 0.001) and aspirin-ticagrelor specifically (aOR = 7.76, 95% CI: 5.65-10.68, <i>P</i> < 0.001). Patients with chronic lung disease (aOR = 0.62, 95% CI: 0.42-0.92, <i>P</i> = 0.02) and a history of angina within two weeks (aOR = 0.69, 95% CI: 0.56-0.85, <i>P</i> < 0.001) were approximately 30% less likely to be prescribed DAPT. Approximately 15% of 1-year all-cause mortality were reported. Older patients prescribed DAPT showed significantly higher survival rates than those who were not (aHR < 1.0, <i>P</i> < 0.001). Aspirin-ticagrelor was associated with higher survival rates than aspirin-clopidogrel (aHR = 0.21, 95% CI: 0.11-0.40, <i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Despite the optimal prescription rate and variation of DAPT in the older Malaysian population, there is room for investigation and improvement in the prescription of newer DAPT combinations that have been suggested to improve patient survival.</p>","PeriodicalId":51294,"journal":{"name":"Journal of Geriatric Cardiology","volume":"22 2","pages":"237-245"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911155/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Geriatric Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26599/1671-5411.2025.02.004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To examine 5-year trends and variations in dual antiplatelet therapy (DAPT) prescription among multiethnic Malaysian patients aged 60 years and older.

Methods: Using the Malaysian National Cardiovascular Disease-Acute Coronary Syndrome (NCVD-ACS) registry, DAPT 5-year temporal trends prescribing patterns at discharge were examined. Multivariate logistic regression was used to calculate the adjusted odds ratio (aOR) of DAPT prescription. The 1-year all-cause mortality by Cox proportional hazard regression model (adjusted hazard ratio, aHR) using inverse proportional weighting covariates adjustment was performed to assess DAPT prognostic impacts.

Results: Data of patients aged 60 years and older were extracted from 2013 to 2017 (n = 3718, mean age: 68 ± 6.74 years, men: 72%, and Malay ethnicity: 43%). The majority of patients were diagnosed with non-ST-segment elevation acute coronary syndrome (63%), predisposed hypertension (76%) and were overweight (74%), while only 35% of patients underwent percutaneous coronary intervention. Over the five years, there was a significant increasing trend in DAPT prescriptions (P < 0.001), with the aspirin-clopidogrel combination being the most common. Aspirin-ticagrelor prescriptions have also increased over the years. Variations in DAPT prescriptions were observed based on patient characteristics. Patients who underwent percutaneous coronary intervention were more likely to be prescribed DAPT in general (aOR = 2.53, 95% CI: 1.95-3.28, P < 0.001) and aspirin-ticagrelor specifically (aOR = 7.76, 95% CI: 5.65-10.68, P < 0.001). Patients with chronic lung disease (aOR = 0.62, 95% CI: 0.42-0.92, P = 0.02) and a history of angina within two weeks (aOR = 0.69, 95% CI: 0.56-0.85, P < 0.001) were approximately 30% less likely to be prescribed DAPT. Approximately 15% of 1-year all-cause mortality were reported. Older patients prescribed DAPT showed significantly higher survival rates than those who were not (aHR < 1.0, P < 0.001). Aspirin-ticagrelor was associated with higher survival rates than aspirin-clopidogrel (aHR = 0.21, 95% CI: 0.11-0.40, P < 0.001).

Conclusions: Despite the optimal prescription rate and variation of DAPT in the older Malaysian population, there is room for investigation and improvement in the prescription of newer DAPT combinations that have been suggested to improve patient survival.

双重抗血小板治疗处方趋势和急性冠状动脉综合征老年人的死亡率结果:来自马来西亚国家心血管疾病数据库的见解
目的:研究60岁及以上马来西亚多民族患者双抗血小板治疗(DAPT)处方的5年趋势和变化。方法:使用马来西亚国家心血管疾病-急性冠状动脉综合征(NCVD-ACS)登记,检查DAPT出院时处方模式的5年时间趋势。采用多因素logistic回归计算DAPT处方的调整优势比(aOR)。1年全因死亡率采用Cox比例风险回归模型(校正风险比,aHR),采用反比例加权协变量调整,评估DAPT对预后的影响。结果:提取2013 - 2017年60岁及以上患者的数据(n = 3718,平均年龄:68±6.74岁,男性:72%,马来族:43%)。大多数患者被诊断为非st段抬高急性冠状动脉综合征(63%),易感高血压(76%)和超重(74%),而只有35%的患者接受了经皮冠状动脉介入治疗。5年间,DAPT处方数量呈显著增加趋势(P < 0.001),其中以阿司匹林-氯吡格雷联合用药最为常见。近年来,阿司匹林-替格瑞洛的处方也有所增加。根据患者特征观察DAPT处方的变化。接受经皮冠状动脉介入治疗的患者更倾向于使用DAPT (aOR = 2.53, 95% CI: 1.95-3.28, P < 0.001)和阿司匹林-替格瑞洛(aOR = 7.76, 95% CI: 5.65-10.68, P < 0.001)。慢性肺病患者(aOR = 0.62, 95% CI: 0.42-0.92, P = 0.02)和两周内有心绞痛史的患者(aOR = 0.69, 95% CI: 0.56-0.85, P < 0.001)服用DAPT的可能性约低30%。大约15%的1年全因死亡率被报道。老年患者接受DAPT治疗的生存率明显高于未接受DAPT治疗的患者(aHR < 1.0, P < 0.001)。阿斯匹林-替格瑞洛的生存率高于阿斯匹林-氯吡格雷(aHR = 0.21, 95% CI: 0.11-0.40, P < 0.001)。结论:尽管DAPT在马来西亚老年人群中的最佳处方率和差异,但在建议提高患者生存率的较新的DAPT组合处方方面仍有研究和改进的空间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Geriatric Cardiology
Journal of Geriatric Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-GERIATRICS & GERONTOLOGY
CiteScore
3.30
自引率
4.00%
发文量
1161
期刊介绍: JGC focuses on both basic research and clinical practice to the diagnosis and treatment of cardiovascular disease in the aged people, especially those with concomitant disease of other major organ-systems, such as the lungs, the kidneys, liver, central nervous system, gastrointestinal tract or endocrinology, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信